Libtayo

Chemical Namecemiplimab-rwlc
Dosage FormInjection (intravenous; 350 mg)
Drug ClassMonoclonal antibodies
SystemSkin
CompanyRegeneron Pharmaceuticals
Approval Year2018

Indication

  • Libtayo is indicated for the treatment of metastatic or locally advanced cutaneous squamous cell carcinoma in patients who are not candidates for curative surgery or curative radiation.
Last updated on 10/30/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Libtayo (Cemiplimab-rwlc) Prescribing Information 2018Regeneron Pharmaceuticals, Tarrytown, NY